GSK will invest $1.2 billion in the development of more than 30 drugs and vaccines for malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance. The company's priorities will include delivering the world's first malaria vaccine and researching a candidate vaccine for tuberculosis. GSK will also produce an adjuvant included in the WHO-recommended malaria vaccine.